Brief: BioXcel Therapeutics Q3 Basic EPS USD -0.32 Vs. IBES Estimate USD -0.54
14/11/2024 12:00
Nov 14 (Reuters) - BioXcel Therapeutics Q3 operating income USD -15.293 million vs. IBES estimate USD -19.1 million. * Q3 revenue USD 214 thousand vs. IBES estimate USD 1.31 million * Q3 operating expenses USD 15.507 million * Q3 net income USD -13.65 million vs. IBES estimate USD -22.3 million
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty